David Caborn, MD
Orthopaedic Surgery · Louisville, KYNPI 1811929961
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $68,520 of the $83,400 with a category attached, or 82.2%. Arthrex accounts for 92.5% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $20,978 and has fallen 97.3% since, to $564 in 2025. Among orthopaedic surgery clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 189 payments — averaging $441.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$77K
- Linvatec Corporation$3K
- Alpha Orthopedic Systems$1K
- Pacira Therapeutics, Inc.$474
- Ferring Pharmaceuticals Inc.$404
- Amgen$286
- plus $1K from 24 others
Across 2 payments — averaging $1050.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Arthrex$1K
- Zimmer Biomet$1K
What the payments were for
- Royalty or licence$68,52082%
- Consulting fees$6,5508%
- Travel & lodging$4,1275%
- Food & beverage$3,0024%
- Education$1,2001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 62 | $77,129 |
| Linvatec Corporation | 3 | $2,802 |
| Alpha Orthopedic Systems | 1 | $1,200 |
| Pacira Therapeutics, Inc. | 26 | $474 |
| Ferring Pharmaceuticals Inc. | 20 | $404 |
| Amgen(2 entities) | 20 | $286 |
| Blue Surgical LLC | 1 | $111 |
| Pacira Pharmaceuticals Incorporated | 6 | $104 |
| Melinta Therapeutics, LLC | 7 | $98 |
| Sanofi-aventis U.S. LLC | 4 | $90 |
| Johnson & Johnson | 5 | $86 |
| Pfizer | 5 | $78 |
| Smith+Nephew | 2 | $65 |
| Heron Therapeutics, Inc. | 3 | $63 |
| Bioventus LLC | 3 | $55 |
| Convatec Inc. | 2 | $46 |
| Avanos Medical | 2 | $40 |
| Dynasplint Systems Inc. | 2 | $30 |
| Solventum Corporation | 2 | $29 |
| KCI USA, Inc. | 2 | $25 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Zimmer Biomet | 1 | $23 |
| Vertex | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Saluda Medical Americas, Inc. | 1 | $19 |
| Orthogenrx Inc. | 1 | $18 |
| AbbVie | 1 | $17 |
| Vericel Corporation | 1 | $15 |
| Orthofix Medical, Inc. | 1 | $14 |
| Flowonix Medical Incorporated | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARTHREX$178,430
- KNEE & HIP IMPLANTS SUSPENSORY FIXATION ACL TIGHTROPE$32,580
- ARTHROPLASTY IMPLANTS KNEE ARTHROPLASTY PATELLO FEMORAL$17,139
- ARTHROPLASTY INSTRUMENTS KNEE ARTHROPLASTY PATELLO FEMORAL$17,139
- ARTHROPLASTY IMPLANTS KNEE ARTHROPLASTY TOTAL KNEE$17,139
- ARTHROPLASTY IMPLANTS KNEE & HIP ARTHROPLASTY PATELLO FEMORAL$9,945
- ARTHROPLASTY INSTRUMENTS KNEE & HIP ARTHROPLASTY PATELLO FEMORAL$9,945
- ARTHROPLASTY IMPLANTS KNEE & HIP ARTHROPLASTY TOTAL KNEE$9,945
- ARTHROPLASTY IMPLANTS TOTAL KNEE ARTHROPLASTY TOTAL KNEE$5,497
- ARTHROPLASTY INSTRUMENTS PARTIAL KNEE ARTHROPLASTY PATELLO FEMORAL$5,497
- ARTHROPLASTY IMPLANTS PARTIAL KNEE ARTHROPLASTY PATELLO FEMORAL$5,497
- ARTHROPLASTY IMPLANTS KNEE ARTHROPLASTY UNI KNEE$4,678
- ALLOGRAFT TISSUE$2,700
How this compares
$83,400 in reported general payments places this provider in the 90th percentile of 322 orthopaedic surgery providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Meloxicam | 40 | $1,177 |
| Celecoxib | 14 | $438 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $81 |
| Tramadol Hcl | 23 | $55 |
| Zolpidem Tartrate | 15 | $38 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Louisville
- Arthur MalkaniLouisville$9.6M
- Jonathan YerasimidesLouisville$4.3M
- John LewisLouisville$1.5M
- Akbar NawabLouisville$1M
- Joseph GreeneLouisville$581K
- George QuillLouisville$304K
- Rodolfo Zamora RendichLouisville$292K
- Richard SweetLouisville$238K
- Frank BonnarensLouisville$146K
- Ryan EadsLouisville$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.